Breast Cancer | Specialty

Accelerated PBI Not Equal to WBI in Ipsilateral Breast Tumor Recurrence

December 7th 2018

Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.

Myelopreservation Possible With CDK4/6 Inhibitor Trilaciclib in TNBC

December 7th 2018

A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.

Lower-Dose Tamoxifen Reduces Recurrence Risk, Toxicity Incidence in Breast Cancer

December 7th 2018

The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.

CTC Counts Demonstrate Selection Value in Metastatic Breast Cancer

December 6th 2018

The use of circulating tumor-cell counts demonstrated strong value for selecting endocrine therapy versus chemotherapy for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Bidard on the Clinical Utility of Circulating Tumor Cell Count in Breast Cancer

December 6th 2018

Francois-Clement Bidard, MD, PhD, professor, medical oncologist, Institut Curie, discusses the clinical utility of circulating tumor cell count (CTC) in breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Dr. Vicini on Partial Breast Irradiation Versus Whole Breast Irradiation in Women With Early-Stage Breast Cancer

December 6th 2018

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, compares the use of partial breast irradiation (PBI) with that of whole breast irradiation (WBI) in women with early-stage breast cancer at the 2018 San Antonio Breast Cancer Symposium.

PD-L1 Immune Cell Expression Critical to Atezolizumab Efficacy in TNBC

December 6th 2018

Improvements observed in progression-free survival and overall survival with the addition of first-line atezolizumab to nab-paclitaxel in patients with metastatic triple negative breast cancer or inoperable locally advanced TNBC are exclusive to those patients with PD-L1 expression ≥1% in immune cells.

Earlier Adjuvant Chemotherapy Benefits Patients With TNBC

December 6th 2018

Delayed treatment with chemotherapy of more than 30 days after surgery for patients with triple-negative breast cancer is associated with worse survival rates and outcomes than those who receive adjuvant chemotherapy within 30 days of their procedure.

Dr. Litton on a Study of Neoadjuvant Talazoparib for Patients With BRCA-Mutated TNBC

December 6th 2018

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses a neoadjuvant study of talazoparib (Talzenna) for patients with BRCA1/2 mutated triple-negative breast cancer (TNBC) during the 2018 San Antonio Breast Cancer Symposium.

Dr. Hershman on Adherence to Cardiovascular Medication and Cardiovascular Events in Breast Cancer

December 6th 2018

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, leader of the breast cancer program at NewYork-Presbyterian/Columbia University Irving Medical Center, discusses the association between cardiovascular medication and cardiovascular events following a diagnosis of early-stage breast cancer during the 2018 San Antonio Breast Cancer Symposium.

Association Between pCR and Neoadjuvant Chemo Shows Improved Breast Cancer Outcomes

December 6th 2018

Pathologic complete response following neoadjuvant chemotherapy appeared to be associated with improved survival outcomes among patients with breast cancer.

Dr. Brufsky on Genomic Assays for Breast Cancer

December 4th 2018

Adam M. Brufsky, MD, PhD, associate director, Clinical Investigation, University of Pittsburgh, discusses genomic assays for breast cancer.

HR+ mBC: Oral Formulations of Docetaxel and Paclitaxel

November 30th 2018

Tesetaxel in Doublet Therapy for HR+ mBC

November 30th 2018

HR+ mBC: Considering the Data and Potential of Tesetaxel

November 30th 2018

Tesetaxel: An Oral Taxane for HR+ mBC

November 30th 2018

Optimizing Selection of Chemotherapy for HR+ mBC

November 30th 2018

Developments in Chemotherapy for HR+ mBC

November 30th 2018

PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer

November 30th 2018

Do CDK4/6 Inhibitors Impact Later Therapy in HR+ mBC?

November 30th 2018